Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has 5 years of Total Non-Current Liabilities data on file, last reported at $210.2 million in Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $210.2 million, down 7.71% year-over-year; the trailing twelve-month figure through Dec 2025 was $210.2 million (down 7.71% YoY), and the FY2025 annual result was $210.2 million, down 7.71% from the prior year.
• Total Non-Current Liabilities eased to $210.2 million in Q4 2025 per RYTM's latest filing, from $227.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $227.7 million in Q4 2024 and troughed at $80.5 million in Q2 2022.
• A 4-year average of $152.3 million and a median of $155.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 57.03% in 2023, then declined 7.71% in 2025.
• A 4-year view of Total Non-Current Liabilities shows it stood at $116.9 million in 2022, then surged by 38.46% to $161.8 million in 2023, then surged by 40.71% to $227.7 million in 2024, then fell by 7.71% to $210.2 million in 2025.
• Business Quant data shows RYTM's Total Non-Current Liabilities at $210.2 million in Q4 2025, $227.7 million in Q4 2024, and $166.8 million in Q2 2024.